Cargando…

Integrin-α(V)-mediated activation of TGF-β regulates anti-tumour CD8 T cell immunity and response to PD-1 blockade

TGF-β is secreted in the tumour microenvironment in a latent, inactive form bound to latency associated protein and activated by the integrin α(V) subunit. The activation of latent TGF-β by cancer-cell-expressed α(V) re-shapes the tumour microenvironment, and this could affect patient responses to P...

Descripción completa

Detalles Bibliográficos
Autores principales:	Malenica, Ines, Adam, Julien, Corgnac, Stéphanie, Mezquita, Laura, Auclin, Edouard, Damei, Isabelle, Grynszpan, Laetitia, Gros, Gwendoline, de Montpréville, Vincent, Planchard, David, Théret, Nathalie, Besse, Benjamin, Mami-Chouaib, Fathia
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8410945/ https://www.ncbi.nlm.nih.gov/pubmed/34471106 http://dx.doi.org/10.1038/s41467-021-25322-y

Ejemplares similares

CD103(+)CD8(+) T(RM) Cells Accumulate in Tumors of Anti-PD-1-Responder Lung Cancer Patients and Are Tumor-Reactive Lymphocytes Enriched with Tc17
por: Corgnac, Stéphanie, et al.
Publicado: (2020)

Regulation of antitumour CD8 T-cell immunity and checkpoint blockade immunotherapy by Neuropilin-1
por: Leclerc, Marine, et al.
Publicado: (2019)

Cancer stem-like cells evade CD8(+)CD103(+) tumor-resident memory T (T(RM)) lymphocytes by initiating an epithelial-to-mesenchymal transition program in a human lung tumor model
por: Corgnac, Stéphanie, et al.
Publicado: (2022)

Tumor-resident memory T cells as a biomarker of the response to cancer immunotherapy
por: Damei, Isabelle, et al.
Publicado: (2023)

The Emerging Role of CD8(+) Tissue Resident Memory T (T(RM)) Cells in Antitumor Immunity: A Unique Functional Contribution of the CD103 Integrin
por: Corgnac, Stéphanie, et al.
Publicado: (2018)

Human preprocalcitonin self-antigen generates TAP-dependent and -independent epitopes triggering optimised T-cell responses toward immune-escaped tumours
por: Durgeau, Aurélie, et al.
Publicado: (2018)

Isolation of tumor-resident CD8(+) T cells from human lung tumors
por: Corgnac, Stéphanie, et al.
Publicado: (2021)

Mutant and non-mutant neoantigen-based cancer vaccines: recent advances and future promises
por: Ashi, Mohamad Omar, et al.
Publicado: (2022)

Resident memory T cells, critical components in tumor immunology
por: Mami-Chouaib, Fathia, et al.
Publicado: (2018)

Recent Advances in Targeting CD8 T-Cell Immunity for More Effective Cancer Immunotherapy
por: Durgeau, Aurélie, et al.
Publicado: (2018)

Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
por: Leclerc, Marine, et al.
Publicado: (2019)

Comment on Hopkins et al. Value of the Lung Immune Prognostic Index in Patients with Non-Small Cell Lung Cancer Initiating First-Line Atezolizumab Combination Therapy: Subgroup Analysis of the IMPOWER150 Trial. Cancers 2021, 13, 1176
por: Auclin, Edouard, et al.
Publicado: (2021)

When Immunity Kills: The Lessons of SARS-CoV-2 Outbreak
por: Taoufik, Yassine, et al.
Publicado: (2021)

Association of the prognostic model iSEND with PD-1/L1 monotherapy outcome in non-small-cell lung cancer
por: Park, Wungki, et al.
Publicado: (2019)

α(E)β(7) integrin interaction with E-cadherin promotes antitumor CTL activity by triggering lytic granule polarization and exocytosis
por: Floc'h, Audrey Le, et al.
Publicado: (2007)

CD8(+)PD-1(+) to CD4(+)PD-1(+) ratio (PERLS) is associated with prognosis of patients with advanced NSCLC treated with PD-(L)1 blockers
por: Duchemann, Boris, et al.
Publicado: (2022)

Editorial: Tissue Resident Memory T Cells
por: Mami-Chouaib, Fathia, et al.
Publicado: (2019)

Vaccine Therapy in Non-Small Cell Lung Cancer
por: García-Pardo, Miguel, et al.
Publicado: (2022)

Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score
por: Pierro, Monica, et al.
Publicado: (2022)

Hypoxic tumor-derived microvesicles negatively regulate NK cell function by a mechanism involving TGF-β and miR23a transfer
por: Berchem, Guy, et al.
Publicado: (2015)

T-cell modulatory properties of CD5 and its role in antitumor immune responses
por: Tabbekh, Mouna, et al.
Publicado: (2013)

Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
por: Robbins, Yvette, et al.
Publicado: (2021)

Chronic Plasma Exposure to Kinase Inhibitors in Patients with Oncogene-Addicted Non-Small Cell Lung Cancer
por: Geraud, Arthur, et al.
Publicado: (2020)

TGF-β attenuates tumour response to PD-L1 blockade by contributing to exclusion of T cells
por: Mariathasan, Sanjeev, et al.
Publicado: (2018)

Correction: Dual PD-L1 and TGF-b blockade in patients with recurrent respiratory papillomatosis
Publicado: (2021)

Impact of Intercurrent Introduction of Steroids on Clinical Outcomes in Advanced Non-Small-Cell Lung Cancer (NSCLC) Patients under Immune-Checkpoint Inhibitors (ICI)
por: De Giglio, Andrea, et al.
Publicado: (2020)

The role of brigatinib in crizotinib-resistant non-small cell lung cancer
por: Mezquita, Laura, et al.
Publicado: (2018)

Integrating Circulating Biomarkers in the Immune Checkpoint Inhibitor Treatment in Lung Cancer
por: Duchemann, Boris, et al.
Publicado: (2020)

Single-cell transcriptomics reveals the effect of PD-L1/TGF-β blockade on the tumor microenvironment
por: Lim, Yoong Wearn, et al.
Publicado: (2021)

Selective inhibition of TGF-β1 produced by GARP-expressing Tregs overcomes resistance to PD-1/PD-L1 blockade in cancer
por: de Streel, Grégoire, et al.
Publicado: (2020)

Pan-TGFβ inhibition by SAR439459 relieves immunosuppression and improves antitumor efficacy of PD-1 blockade
por: Greco, Rita, et al.
Publicado: (2020)

TGF-β inhibition can overcome cancer primary resistance to PD-1 blockade: A mathematical model
por: Siewe, Nourridine, et al.
Publicado: (2021)

B-cells Drive Response to PD-1 Blockade in Glioblastoma Upon Neutralization of TGFβ-mediated Immunosuppression
por: Hou, David, et al.
Publicado: (2023)

Synergistic efficacy of simultaneous anti-TGF-β/VEGF bispecific antibody and PD-1 blockade in cancer therapy
por: Niu, Mengke, et al.
Publicado: (2023)

An integrative modeling framework reveals plasticity of TGF-β signaling
por: Andrieux, Geoffroy, et al.
Publicado: (2014)

α1A Adrenoreceptor blockade attenuates myocardial infarction by modulating the integrin-linked kinase/TGF-β/Smad signaling pathways
por: Alrasheed, Nawal M., et al.
Publicado: (2023)

Prognostic value of tumor mutations in radically treated locally advanced non-small cell lung cancer patients
por: Boros, Angela, et al.
Publicado: (2017)

Secreted PD-L1 variants mediate resistance to PD-L1 blockade therapy in non–small cell lung cancer
por: Gong, Bo, et al.
Publicado: (2019)

Selection of tumor-resistant variants following sustained natural killer cell-mediated immune stress
por: Carré, Thibault, et al.
Publicado: (2021)

TGFβ: Signaling Blockade for Cancer Immunotherapy
por: Chen, Szu-Ying, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rvb2lml0omg8osqpg1lrjdqbii